[Federal Register Volume 81, Number 30 (Tuesday, February 16, 2016)]
[Notices]
[Page 7783]
[FR Doc No: 2016-03023]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. PR15-26-000]

Enterprise Texas Pipeline LLC; Notice of Informal Settlement
Conference

    Take notice that an informal settlement conference will be convened
in the above-captioned proceeding on February 24, 2016, at 10:00 a.m.
(EDT), in a room to be designated at the offices of the Federal Energy
Regulatory Commission, 888 First Street NE., Washington, DC 20426, for
the purpose of exploring the possible settlement of the above-
referenced docket.
    At the conference, Enterprise Texas Pipeline LLC should be prepared
to provide, as necessary, additional support for its position.
    FERC conferences are accessible under section 508 of the
Rehabilitation Act of 1973. For accessibility accommodations please
send an email to<EMAIL_ADDRESS>or call toll free (866) 208-
3372 (voice) or<PHONE_NUMBER> (TTY), or send a fax to<PHONE_NUMBER> with
the required accommodations.
    All interested parties and staff are permitted to attend. For
further information please contact David Tishman at<PHONE_NUMBER> or
email at<EMAIL_ADDRESS>or Seong-Kook Berry at<PHONE_NUMBER>
or email at<EMAIL_ADDRESS>
    Dated: February 9, 2016.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2016-03023 Filed 2-12-16; 8:45 am]
BILLING CODE 6717-01-P


------

			  UNITED STATES OF AMERICA

		        DEPARTMENT OF TRANSPORTATION

			  OFFICE OF THE SECRETARY

			          WASHINGTON, D.C.

Issued by the Department of Transportation on June 6, 2005

NOTICE OF ACTION TAKEN -- DOCKETS OST-2002-130612005-21033

                                     OST-2002-13011

________________________________________________________________________
________________________________________________________

This serves as notice to the public of the action described below, taken
by the Department official indicated (no additional confirming order
will be issued in this matter).

Applications of     FRONTIER AIRLINES, INC. (FRONTIER)  filed
6/11/20044/18/2005 for:

XX  Exemption for two years under 49 U.S.C. 40109 to provide the
following service:Renewal of exemption for two years under 49 U.S.C.
40109 to provide the following service:

Docket OST-2002-13061:

Scheduled foreign air transportation of persons, property, and mail
between (1) the terminal point Denver, Colorado, and the terminal point
CancunCozumel, Mexico; (2) the terminal point Kansas City, Missouri, and
the terminal point Puerto Vallarta, Mexico; and (3) the terminal point
Salt Lake City, Utah, and the terminal point Puerto Vallarta, Mexico.
Frontier proposes to operate these services beginning on or about
November 18, 2005.

.

Docket OST-2002-13011:

Scheduled foreign air transportation of persons, property, and mail
between (1) the terminal point Denver, Colorado, and the terminal point
San Jose del Cabo, Mexico; and (2) the terminal point

Denver, Colorado, and the terminal point Mazatlan, Mexico..  Frontier
requested that the authority be

renewed through August 23, 2006.

Applicant rep:   Edward P. Faberman<PHONE_NUMBER>719-7402    DOT
Analyst:  Linda L. LundellThuy H. Cooper<PHONE_NUMBER>5423

D I S P O S I T I O N

XX  Granted renewal of exemption authority for two years (subject to
conditions, see below)

XX  Dismissed request for longer-term authority (see remarks, below)

The above action was effective when taken:   : June 6, 2005 through
through June 6, 2007.

Action taken by:   Paul L. Gretch, Director

		      Office of International Aviation

XX   The authority granted is consistent with the aviation agreement
between the United States and Mexico.

Except to the extent exempted or waived, this authority is subject to
the terms, conditions, and limitations indicated:     		XX  Holder’s
certificates of public convenience and necessity

		XX  Standard Exemption Conditions (attached)

------------------------------------------------------------------------
------------------------------------------------------------------------
-------------------------------------------------------

Conditions:  The U.S.-Mexico exemption authority granted is subject to
the dormancy notice requirements set forth in condition 7 of Appendix A
of Order 88-10-2.  The U.S.-Mexico exemption authority granted is
subject to the dormancy notice requirements set forth in condition 7 of
Appendix A of Order 88-10-2.  Consistent with our policy, the dormancy
notice period will begin on November 18, 2005, Frontier’s proposed
start-up date for the above-mentioned service.

Responsive Pleadings: Delta Air Lines, Inc. (Delta), United Air Lines,
Inc. (United), and the City of Kansas City (Kansas City) filed answers
in response to certain portions of Frontier’s application.  Frontier
filed a response to the answers of Delta and United.  Kansas City
supports Frontier’s application for Kansas City-Puerto Vallarta
service.  Delta states that it has no objection to Frontier’s request
for Salt Lake City-Puerto Vallarta authority, provided that Delta’s
exemption application for this market is granted simultaneously (see
Delta application in Docket OST-2005-21075).  United states that it has
no objection to Frontier’s request for Denver-Cozumel authority,
provided that United’s exemption application for this market is
granted contemporaneously (see United application in Docket

OST-2005-21162).  We have, today, granted each of the referenced
applications.

Remarks:  In its application, Frontier requested that the subject
authority be renewed through August 23, 2006.  Consistent with our
standard practice for this type of application, we renewed Frontier’s
authority for two years and dismissed its request for longer-term
authority.

------------------------------------------------------------------------
---------------------------------------------------------------------

On the basis of data officially noticeable under Rule 24(g) of the
Department’s regulations, we found the applicant qualified to provide
the services authorized.

Under authority assigned by the Department in its regulations, 14 CFR
Part 385, we found that (1) our action was consistent with Department
policy; (2) grant of the authority was consistent with the public
interest; and (3) grant of the authority would not constitute a major
regulatory action under the Energy Policy and Conservation Act of 1975.
To the extent not granted or dismissed, we denied all requests in the
referenced Dockets.  We may amend, modify, or revoke the authority
granted in this Notice at any time without hearing at our discretion.

Persons entitled to petition the Department for review of the action set
forth in this Notice under the Department’s regulations, 14 CFR
§385.30, may file their petitions within seven (7) days after the date
of issuance of this Notice.  This action was effective when taken, and
the filing of a petition for review will not alter such effectiveness.

An electronic version of this document is available on the World Wide
Web at:

  HYPERLINK "http://dms.dot.gov//reports/reports_aviation.asp"
http://dms.dot.gov//reports/reports_aviation.asp

U.S. Carrier Exemption Conditions

In the conduct of the operations authorized, the U.S. carrier
applicant(s) shall:

(1)  Hold at all times effective operating authority from the government
of each country served;

(2)  Comply with applicable requirements concerning oversales contained
in 14 CFR 250 (for scheduled operations, if authorized);

(3)  Comply with the requirements for reporting data contained in 14 CFR
241;

(4)  Comply with requirements for minimum insurance coverage, and for
certifying that coverage to the Department, contained in 14 CFR 205;

(5)  Except as specifically exempted or otherwise provided for in a
Department Order, comply with the requirements of 14 CFR 203, concerning
waiver of Warsaw Convention liability limits and defenses;

(6)  Comply with all applicable requirements of the Federal Aviation
Administration and with all applicable U.S. Government requirements
concerning security, including, but not limited to, 49 CFR Part 1544.
To assure compliance with all applicable U.S. Government requirements
concerning security, the holder shall, before commencing any new service
(including charter flights) to or from a foreign airport, contact its
International Principal Security Inspector (IPSI) to advise the IPSI of
its plans and to find out whether the Transportation Security
Administration has determined that security is adequate to allow such
airport(s) to be served; and

(7)  Comply with such other reasonable terms, conditions, and
limitations required by the public interest as may be prescribed by the
Department of Transportation, with all applicable orders and regulations
of other U.S. agencies and courts, and with all applicable laws of the
United States.

The authority granted shall be effective only during the period when the
holder is in compliance
w瑩桴潣摮瑩潩獮椠灭獯摥愠潢敶മ഍഍഍഍഍㔰
㈯〰ഴȍ†传彟彟彟彟ⱟ㜠㈯⼳㌰桴敄慰瑲敭瑮
愠灰潲敶桴慣牲敩鉲⁳敲畱獥⁴潴挠湯敶瑲椠獴䐠
湥敶⵲慍慺汴湡猠牥楶散⁳牦浯礠慥⵲潲湵潴猠慥潳
慮⹬†汁瑯敨⁲敳癲捩獥愠敲漠晦牥摥漠敹牡爭
畯摮戠獡獩മ


[Federal Register Volume 79, Number 221 (Monday, November 17, 2014)]
[Notices]
[Pages 68437-68438]
[FR Doc No: 2014-27095]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER15-297-000; LDVF1 TEP LLC]

Supplemental Notice That Initial Market-Based Rate Filing
Includes Request for Blanket Section 204 Authorization

    This is a supplemental notice in the above-referenced proceeding of
LDVF1 TEP LLC's application for market-based rate authority, with an
accompanying rate tariff, noting that such application includes a
request for blanket authorization, under 18 CFR part 34, of future
issuances of securities and assumptions of liability.
    Any person desiring to intervene or to protest should file with the
Federal Energy Regulatory Commission, 888 First Street NE., Washington,
DC 20426, in accordance with Rules 211 and 214 of the Commission's
Rules of Practice and Procedure (18 CFR 385.211 and 385.214). Anyone
filing a motion to intervene or protest must serve a copy of that
document on the Applicant.
    Notice is hereby given that the deadline for filing protests with
regard to the applicant's request for blanket authorization, under 18
CFR part 34, of future issuances of securities and assumptions of
liability, is November 28, 2014.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov. To facilitate electronic service, persons with Internet
access who will eFile a document and/or be

listed as a contact for an intervenor must create and validate an
eRegistration account using the eRegistration link. Select the eFiling
link to log on and submit the intervention or protests.
    Persons unable to file electronically should submit an original and
5 copies of the intervention or protest to the Federal Energy
Regulatory Commission, 888 First Street NE., Washington, DC 20426.
    The filings in the above-referenced proceeding are accessible in
the Commission's eLibrary system by clicking on the appropriate link in
the above list. They are also available for electronic review in the
Commission's Public Reference Room in Washington, DC. There is an
eSubscription link on the Web site that enables subscribers to receive
email notification when a document is added to a subscribed docket(s).
For assistance with any FERC Online service, please email
<EMAIL_ADDRESS>or call<PHONE_NUMBER> (toll free). For
TTY, call<PHONE_NUMBER>.

    Dated: November 7, 2014.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2014-27095 Filed 11-14-14; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 83, Number 30 (Tuesday, February 13, 2018)]
[Notices]
[Pages 6188-6190]
[FR Doc No: 2018-02923]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2018-N-0235]

Orthopaedic Sensing, Measuring, and Advanced Reporting Technology
Devices; Public Workshop; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is
announcing the following public workshop entitled ``Orthopaedic
Sensing, Measuring, and Advanced Reporting Technology (SMART)
Devices.'' The purpose of the public workshop is to discuss the
development of Orthopaedic SMART Devices. The workshop is intended to
enhance engagement with stakeholders to facilitate device development
and to discuss scientific and regulatory challenges associated with
Orthopaedic SMART Devices. Public input and feedback gained through
this workshop may aid in the efficient development of innovative, safe,
and effective Orthopaedic SMART Devices for better patient care.

DATES: The public workshop will be held on April 30, 2018, from 8:30
a.m. to 5 p.m. Submit either electronic or written comments on this
public workshop by May 29, 2018. See the SUPPLEMENTARY INFORMATION
section for registration date and information.

ADDRESSES: The public workshop will be held at FDA's White Oak Campus,
10903 New Hampshire Ave., Bldg. 31, Rm. 1503 (The Great Room), Silver
Spring, MD 20993. Entrance for the public workshop participants (non-
FDA employees) is through Building 1 where routine security check
procedures will be performed. For parking and security information,
please refer to https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.
    You may submit comments as follows. Please note that late, untimely
filed comments will not be considered. Electronic comments must be
submitted on or before May 29, 2018. The https://

www.regulations.gov electronic filing system will accept comments until
midnight Eastern Time at the end of May 29, 2018. Comments received by
mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2018-N-0235 for ``Orthopaedic Sensing, Measuring, and Advanced
Reporting Technology Devices; Public Workshop; Request for Comments.''
Received comments, those filed in a timely manner (see ADDRESSES), will
be placed in the docket and, except for those submitted as
``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Andrew Baumann, Food and Drug
Administration, Center for Devices and Radiological Health, 10903 New
Hampshire Ave., Bldg. 62, Rm. 2110, Silver Spring, MD 20993, 301-796-
2508, [email protected].

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is sponsoring a public workshop to discuss the engineering,
clinical, regulatory, cybersecurity, and real world evidence aspects of
Orthopaedic SMART Devices. The technologies of interest incorporate
sensor equipped implants and instruments that generate information
related to orthopaedic device performance and patient health. FDA
understands that these technologies will play a role in the future of
orthopaedics by providing objective data to the appropriate stakeholder
that may optimize patient care. A public discussion of these topics
will help the orthopaedic medical device community better understand
the development of and considerations for these technologies. The
workshop may help FDA and stakeholders prepare for the submittal and
review of related applications.

II. Topics for Discussion at the Public Workshop

    The public workshop will consist of presentations and panel
discussions. Presentations will frame the topic and provide information
on specific aspects of orthopaedic SMART device technology. Following
the presentations, moderated discussions will ask speakers and
additional panelists to provide their individual perspectives. Four
rounds of presentations and panel discussions will cover the following
topics:

 Engineering/Technology (morning)

    This session will introduce orthopaedic sensor technologies and
cover the current state of research and industry adoption. Future
applications of these technologies will be explored.

 Clinical/Patient perspective (morning)

    This session will cover the importance and potential utility of
these technologies for clinicians and patients. Considerations for
adopting these new technologies into existing health care paradigms
will be discussed.

 Cybersecurity (afternoon)

    This session will cover current cybersecurity issues and
considerations. An overview of FDA's cybersecurity considerations and
guidance documents will be presented.

 Regulatory Considerations (afternoon)

    This session will discuss FDA's current and evolving thinking on
Digital Health, clinical study considerations, including the role of
real-world evidence, relevant guidance documents, and evidence
generation related to Orthopaedic SMART Devices.
    A detailed agenda will be posted on the following website in
advance of the workshop: https://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm and select this event from the list of
items provided.

III. Participating in the Public Workshop

    Registration: To register for the public workshop, please visit
FDA's Medical

Devices News & Events--Workshops & Conferences calendar at http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm.
(Select this public workshop from the posted events list.) Please
provide complete contact information for each attendee, including name,
title, affiliation, address, email, and telephone.
    Registration is free and based on space availability, with priority
given to early registrants. Persons interested in attending this public
workshop must register by April 20, 2018, by 4 p.m. Eastern Time. Early
registration is recommended because seating is limited; therefore, FDA
may limit the number of participants from each organization.
Registrants will receive confirmation when they have been accepted. If
time and space permit, onsite registration on the day of the public
workshop will be provided beginning at 7:30 a.m. We will let
registrants know if registration closes before the day of the public
workshop.
    If you need special accommodations due to a disability, please
contact Susan Monahan, Center for Devices and Radiological Health, Food
and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5231,
Silver Spring, MD 20993-0002,<PHONE_NUMBER>, email:
[email protected], no later than April 16, 2018.
    Streaming Webcast of the Public Workshop: This public workshop will
also be webcast. The webcast link will be available on the registration
web page after April 20, 2018. Organizations are requested to register
all participants, but to view using one connection per location.
    If you have never attended a Connect Pro event before, test your
connection at https://collaboration.fda.gov/common/help/en/support/meeting_test.htm. To get a quick overview of the Connect Pro program,
visit https://www.adobe.com/go/connectpro_overview. FDA has verified
the website addresses in this document, as of the date this document
publishes in the Federal Register, but websites are subject to change
over time.
    Transcripts: Please be advised that as soon as a transcript of the
public workshop is available, it will be accessible at https://www.regulations.gov. It may be viewed at the Dockets Management Staff
(see ADDRESSES). A link to the transcript will also be available
approximately 45 days after the public workshop on the internet at
http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm. (Select this public workshop from the posted events list).

    Dated: February 8, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-02923 Filed 2-12-18; 8:45 am]
 BILLING CODE 4164-01-P


[Federal Register Volume 79, Number 139 (Monday, July 21, 2014)]
[Notices]
[Page 42384]
[FR Doc No: 2014-17188]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

Sunshine Act Meeting

    Notice is hereby given, pursuant to the provisions of the
Government in the Sunshine Act, Public Law 94-409, that the Securities
and Exchange Commission will hold an Open Meeting on July 25, 2014, at
10 a.m., in the Auditorium (L-002) at the Commission's headquarters
building, to hear oral argument in an appeal by the Division of
Enforcement from an initial decision of an administrative law judge.
    On October 28, 2011, the law judge dismissed proceedings brought by
the Division against Respondents John P. Flannery and James D. Hopkins,
former employees of State Street Bank and Trust Company. The law judge
held that Respondents did not violate the antifraud provisions of
Section 17(a) of the Securities Act of 1933, Section 10(b) of the
Securities Exchange Act of 1934, and Exchange Act Rule 10b-5 because
she found that, among other things, they did not make misleading
statements regarding the portfolio holdings of an unregistered
collective trust fund, the Limited Duration Bond Fund (``LDBF''), in
communications with LDBF investors.
    The issues likely to be considered at oral argument include whether
Respondents violated the antifraud provisions as alleged and, if so,
the extent to which they should be sanctioned for those violations.
    For further information, please contact the Office of the Secretary
at<PHONE_NUMBER>.

    Dated: July 17, 2014.
Kevin M. O'Neill,
Deputy Secretary.
[FR Doc. 2014-17188 Filed 7-17-14; 11:15 am]
BILLING CODE 8011-01-P